我公司致力于為客戶提供高純度、低成本的活性重組蛋白，包括重組人含表皮生長(zhǎng)因子樣重復(fù)區(qū)和盤在內(nèi)的各類受體、細(xì)胞因子、生長(zhǎng)因子、轉(zhuǎn)錄因子、激素、酶、毒性蛋白、病毒抗原等。

北京百奧萊博科技有限公司是一家專業(yè)的生物試劑銷售公司。公司主要經(jīng)營(yíng)血清、抗原、抗體等生物試劑產(chǎn)品，可以為您提供專業(yè)的技術(shù)服務(wù)，以優(yōu)良的價(jià)格、優(yōu)質(zhì)的服務(wù)、優(yōu)先的理念，滿足客戶的各方面的需求，與國(guó)內(nèi)多家企業(yè)、單位建立了良好的長(zhǎng)期合作關(guān)系，擁有較好的企業(yè)信譽(yù)和品牌形象。 主營(yíng)產(chǎn)品:血清、抗體、抗原、核酸提取、核酸純化等生化試劑

特別提示：包括重組人含表皮生長(zhǎng)因子樣重復(fù)區(qū)和盤狀結(jié)構(gòu)域1的蛋白3(EDIL3)在內(nèi)，本公司的所有產(chǎn)品僅可用于科研實(shí)驗(yàn)，嚴(yán)禁用于臨床醫(yī)療及其他非科研用途！

產(chǎn)品名稱：重組人含表皮生長(zhǎng)因子樣重復(fù)區(qū)和盤狀結(jié)構(gòu)域1的蛋白3(EDIL3)
英文名稱：Recombinant Human EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3
產(chǎn)品貨號(hào)：JN0642
產(chǎn)品規(guī)格：10μg|50μg|500μg|1mg

本品由我們的哺乳動(dòng)物細(xì)胞表達(dá)系統(tǒng)制備而成，目的基因編碼的Val17-Glu480在C端含有His標(biāo)簽。

EDIL3質(zhì)量控制：＞95%(還原性SDS-PAGE)

EDIL3制劑：凍干品

EDIL3保存：
凍干蛋白置于-20℃以下可長(zhǎng)期保存，室溫條件下可穩(wěn)定保存3周。
復(fù)溶蛋白溶液可在4～7℃保存2～7天，可分裝后置于-20℃保存三個(gè)月。

EDIL3復(fù)溶：
打開(kāi)試劑管前請(qǐng)先離心。
復(fù)溶濃度推薦大于100 μg/ml。
凍干蛋白請(qǐng)溶于ddH2O。
復(fù)溶后，請(qǐng)根據(jù)用量分裝凍存，避免反復(fù)凍融。

關(guān)于EDIL3：
EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3 (EDIL3) is a 52 kDa extracellular matrix protein that is expressed by endothelial tissues during embryonic vascular development. EDIL3 becomes quiescent at the time of birth, and is no longer expressed in normal adult tissues. EDIL3 has been found to be re-expressed in a number of human tumors as well as in ischemic muscles and ischemic brain tissue, which may play an important role in adult angiogenesis. EDIL3 promotes adherence and migration of endothelial cells, and acts as an endothelial cell survival agent through upregulation of Bcl-2 expression. EDIL3 has also been shown to be an endogenous inhibitor of inflammatory cell recruitment by interfering with the integrin LFA-1-dependent leukocyte-endothelial adhesion. Human EDIL3 is synthesized as a precursor with a 16 amino acid signal sequence and a 464 amino acid mature chain.

根據(jù)您的關(guān)注的重組人含表皮生長(zhǎng)因子樣重復(fù)區(qū)和盤狀結(jié)構(gòu)域1的蛋白3(EDIL3)，重組人含表皮生長(zhǎng)因子樣重復(fù)區(qū)和盤狀結(jié)構(gòu)域1的蛋白3(EDIL3)，rhEDIL3，EDIL3，重組人EDIL3，重組EDIL3，rEDIL3，重組人含表皮生長(zhǎng)因子樣重復(fù)區(qū)和盤狀結(jié)構(gòu)域1的蛋白3，重組人EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3，重組EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3，Recombinant Human EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3，重組含表皮生長(zhǎng)因子樣重復(fù)區(qū)和盤狀結(jié)構(gòu)域1的蛋白3，JN0642，百奧萊博，，，您可能還對(duì)以下產(chǎn)品有需求：


JN0228 重組人酸性FGF1(成纖維細(xì)胞生長(zhǎng)因子1) 10μg|50μg|500μg|1mg
JN0409 重組人白介素IL-2Rγ(白細(xì)胞介素2Rγ) 10μg|50μg|500μg|1mg
JN0457 重組人腫瘤壞死因子受體超家族成員12A(TNFRSF12A) 10μg|50μg|500μg|1mg
JN0460 重組人Fas(TNFRSF6)(CD95) 10μg|50μg|500μg|1mg
JN2028 重組人S100-P蛋白 10μg|50μg|500μg|1mg
JN0514 重組人碳酸酐酶10(CA10) 10μg|50μg|500μg|1mg
JN0596 重組人神經(jīng)營(yíng)養(yǎng)酪氨酸激酶受體2型(NTRK2) 10μg|50μg|500μg|1mg

關(guān)注重組人含表皮生長(zhǎng)因子樣重復(fù)區(qū)和盤狀結(jié)構(gòu)域1的蛋白3(EDIL3)，重組人含表皮生長(zhǎng)因子樣重復(fù)區(qū)和盤狀結(jié)構(gòu)域1的蛋白3(EDIL3)，rhEDIL3，EDIL3，重組人EDIL3，重組EDIL3，rEDIL3，重組人含表皮生長(zhǎng)因子樣重復(fù)區(qū)和盤狀結(jié)構(gòu)域1的蛋白3，重組人EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3，重組EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3，Recombinant Human EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3，重組含表皮生長(zhǎng)因子樣重復(fù)區(qū)和盤狀結(jié)構(gòu)域1的蛋白3，JN0642，百奧萊博，，的同時(shí)，為您推薦更多您可能感興趣的產(chǎn)品：



名稱：重組人趨化因子CXCL2(MIP-2)
貨號(hào)：JN0298
規(guī)格：10μg|50μg|500μg|1mg
本品由我們的大腸桿菌表達(dá)系統(tǒng)制備，目的基因編碼的Thr39-Asn107表達(dá)純化而來(lái)。

CXCL2/MIP-2質(zhì)量控制：＞95%(還原性SDS-PAGE)。

CXCL2/MIP-2制劑：凍干品

CXCL2/MIP-2保存：
凍干蛋白可在-20℃長(zhǎng)期保存，室溫也可穩(wěn)定保存3周。
復(fù)溶蛋白溶液可在4～7℃保存2～7天。
復(fù)溶后建議分裝凍存在-20℃，可保存3個(gè)月，應(yīng)避免反復(fù)凍融。

CXCL2/MIP-2復(fù)溶：
1、試劑開(kāi)蓋前請(qǐng)先離心。
2、復(fù)溶濃度應(yīng)大于100 μg/ml.
3、凍干蛋白溶于ddH2O中
4、復(fù)溶后根據(jù)使用量分裝保存，避免反復(fù)凍融。

關(guān)于CXCL2/MIP-2：
Chemokine Ligand 2 (CXCL2) is a small secreted cytokine which belongs to the CXC chemokine family. It is secreted by monocytes and macrophages and chemotactic for polymorphonuclear leukocytes and hematopoietic stem cells. CXCL2 mobilizes cells by interacting with a cell surface chemokine receptor called CXCR2. It has been known to regulate immune functions mainly by chemo-attracting neutrophils. It is produced by activated monocytes and neutrophils and expressed at sites of inflammation. It is a hematoregulatory chemokine, which suppresses hematopoietic progenitor cell proliferation. It can be induced by receptor activator of NF-kappaB ligand, the osteoclast (OC) differentiation factor, through JNK and NF-kappaB signaling pathways in OC precursor cells. CXCL2 in turn enhanced the proliferation of OC precursor cells of bone marrow-derived macrophages (BMMs) through the activation of ERK. Knockdown of CXCL2 inhibited both the proliferation of and the ERK activation in BMMs. During osteoclastogenesis CXCL2 stimulated the adhesion and the migration of BMMs. CXCL2 is a novel therapeutic target for inflammatory bone destructive diseases.

本頁(yè)產(chǎn)品地址：http://m.521uz.com/sell/show-8529010.html